Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Geddes

Showing results (91-100 of 113) with videos related to

Pageof 12
Sort By:
Journal of Medical Internet Research|January 16, 2020
The True Colours Remote Symptom Monitoring System: A Decade of EvolutionSarah M Goodday, Lauren Atkinson, Guy Goodwin, et al.
Journal of Affective Disorders|July 19, 2025
Cost-effectiveness of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression: Economic evaluation of the PAX-BD randomised controlled trialMichael Berger, Timea Helter, Lumbini Azim, et al.
Journal of Crohn'S & Colitis|July 22, 2022
Patient-reported Outcomes: the ICHOM Standard Set for Inflammatory Bowel Disease in Real-life Practice Helps Quantify Deficits in Current CareDarren Wong, Lawrence Matini, Andrey Kormilitzin, et al.
Health Technology Assessment (Winchester, England)|May 12, 2025
Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression in adults: LQD a pragmatic randomised controlled trialJess Kerr-Gaffney, Zohra Zenasni, Kimberley Goldsmith, et al.
Journal of Global Health|December 6, 2022
Setting national research priorities for difficult-to-treat depression in the UK between 2021-2026Natalya Chapman, Michael Browning, David Baghurst, et al.
Evidence-Based Mental Health|September 29, 2021
Impact of COVID-19 on telepsychiatry at the service and individual patient level across two UK NHS mental health TrustsJames Sw Hong, Rebecca Sheriff, Katharine Smith, et al.
Health Technology Assessment (Winchester, England)|April 21, 2016
Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trialThomas R E Barnes, Verity C Leeson, Carol Paton, et al.
Trials|August 1, 2021
An Investigation of Levetiracetam in Alzheimer's Disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept studyArjune Sen, Mary Akinola, Xin You Tai, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|June 4, 2026
Recommendations of the ECNP Digital Network for the evaluation of mental health care apps: A Delphi consensusBlanca Bolea, Diego Hidalgo-Mazzei, John Geddes, et al.
Epilepsia Open|October 14, 2024
Safety, tolerability, and efficacy outcomes of the Investigation of Levetiracetam in Alzheimer's disease (ILiAD) study: a pilot, double-blind placebo-controlled crossover trialArjune Sen, Sofia Toniolo, Xin You Tai, et al.
Pageof 12

Showing results (91-100 of 113) with videos related to

Sort By:
Pageof 12
Journal of Medical Internet Research|January 16, 2020
The True Colours Remote Symptom Monitoring System: A Decade of EvolutionSarah M Goodday, Lauren Atkinson, Guy Goodwin, et al.
Journal of Affective Disorders|July 19, 2025
Cost-effectiveness of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression: Economic evaluation of the PAX-BD randomised controlled trialMichael Berger, Timea Helter, Lumbini Azim, et al.
Journal of Crohn'S & Colitis|July 22, 2022
Patient-reported Outcomes: the ICHOM Standard Set for Inflammatory Bowel Disease in Real-life Practice Helps Quantify Deficits in Current CareDarren Wong, Lawrence Matini, Andrey Kormilitzin, et al.
Health Technology Assessment (Winchester, England)|May 12, 2025
Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression in adults: LQD a pragmatic randomised controlled trialJess Kerr-Gaffney, Zohra Zenasni, Kimberley Goldsmith, et al.
Journal of Global Health|December 6, 2022
Setting national research priorities for difficult-to-treat depression in the UK between 2021-2026Natalya Chapman, Michael Browning, David Baghurst, et al.
Evidence-Based Mental Health|September 29, 2021
Impact of COVID-19 on telepsychiatry at the service and individual patient level across two UK NHS mental health TrustsJames Sw Hong, Rebecca Sheriff, Katharine Smith, et al.
Health Technology Assessment (Winchester, England)|April 21, 2016
Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trialThomas R E Barnes, Verity C Leeson, Carol Paton, et al.
Trials|August 1, 2021
An Investigation of Levetiracetam in Alzheimer's Disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept studyArjune Sen, Mary Akinola, Xin You Tai, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|June 4, 2026
Recommendations of the ECNP Digital Network for the evaluation of mental health care apps: A Delphi consensusBlanca Bolea, Diego Hidalgo-Mazzei, John Geddes, et al.
Epilepsia Open|October 14, 2024
Safety, tolerability, and efficacy outcomes of the Investigation of Levetiracetam in Alzheimer's disease (ILiAD) study: a pilot, double-blind placebo-controlled crossover trialArjune Sen, Sofia Toniolo, Xin You Tai, et al.
Pageof 12